At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALZN Alzamend Neuro, Inc
Market Closed 05-17 16:00:00 EDT
0.6336
-0.0154
-2.37%
盘后0.6650
+0.0314+4.96%
19:32 EDT
High0.6785
Low0.6001
Vol32.28K
Open0.6347
D1 Closing0.6490
Amplitude12.08%
Mkt Cap4.36M
Tradable Cap3.07M
Total Shares6.88M
T/O21.06K
T/O Rate0.67%
Tradable Shares4.85M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Alzamend Neuro Unveils Updated Investor Presentation Outlook
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.